More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS) ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center (TTUHSC) and director of the ...

Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- ...

Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium. Following the 2025 Annual ASCO Genitourinary Cancers Symposium, Dr ...

The Lenvima and Welireg combination shows promise in treating metastatic clear cell RCC, with a 47% response rate in phase 2 trials. KIM-1 is emerging as a significant biomarker for prognosis and ...

Detalimogene voraplasmid is a novel, investigational, pivotal-stage, non-viral genetic medicine designed to mitigate systemic risks and deliver durable efficacy for patients with high-risk NMIBC, ...

A secondary analysis of the phase III VISION trial presented at this year's American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium found that adding androgen receptor pathway ...

Sarcopenia as a marker to assess the surveillance necessity after a 5-year cancer-free period in patients who undergo radical cystectomy: A multi-institutional retrospective study.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers ...

TTUHSC’s Thomas E. Hutson, D.O., Pharm.D., Ph.D., shared groundbreaking findings from the landmark CLEAR study Feb. 13-14 at the 2025 American Society of Clinical ...